Glepaglutide

Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3].

Research Areas >> Inflammation/Immunology

GLP-2R[3]

Glepaglutide (200 and 400 nmol/kg, s.c., twice a day for 14 days) shows intestinotrophic effect in rats with small intestinal inflammation[3]. Animal Model: Rats with Indomethacin (HY-14397)-induced small intestinal inflammation[3] Dosage: 200 and 400 nmol/kg Administration: Subcutaneousinjection (s.c.), twice a day for 14 days. Result: Increased plasma citrulline concentration. Increased small intestinal mass. Decreased small intestinal concentrations of the inflammatory marker (AGP and MPO).